NDC 3215-6522-01 - Buprenorphine and Naloxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 3215-6522
- Requested NDC
- 3215-6522-01
- Package NDCs from labels
- 3215-6522-01, 3215-6522-30
- Manufacturer
- Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC
- Effective date
- 2026-04-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine and Naloxone - Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | 2026-04-07 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 3215-6522-01 | Buprenorphine and Naloxone | 1 in 1 POUCH | FILM | 1 | 2 | |
| 3215-6522-30 | Buprenorphine and Naloxone | 30 in 1 CARTON | FILM | 30 | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CitriPlus | JUGLANS REGIA WHOLE AND ANHYDROUS CITRIC ACID | PEKANA Natuheilmittel GmbH | 11db1b5b-2959-42c4-a059-25c951933004 | 2023-01-11 | Warnings | XF417D3PSL |
| Glucoreg | ASCORBICUM ACIDUM, PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, SARCOLACTICUM ACIDUM, THIAMINUM HYDROCHLORICUM, DHEA (DEHYDROEPIANDROSTERONE), PHLORIDZINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ALPHA-LIPOICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, NADIDUM, PANTOTHENIC ACID, ACETALDEHYDE, INSULINUM (SUIS), INSULINUM (HUMAN), HEPAR SUIS, PANCREAS SUIS, PHLORIDZINUM, BARYTA OXALICA, ALLOXANUM, BERBERIS VULGARIS, CARCINOSIN, LYCOPODIUM CLAVATUM, MOMORDICA BALSAMINA, PHOSPHORICUM ACIDUM, PHOSPHORUS, | Deseret Biologicals, Inc. | 5117f980-95b8-4fc8-9425-8f6f05639437 | 2022-12-29 | Warnings | XF417D3PSL |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co. LLC, DBA HealthFirst | 74fcd243-94b3-ec77-e053-2991aa0a229c | 2022-12-09 | Warnings, Adverse reactions | F850569PQR |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) SOLUTION | Fenwal, Inc. | d55cb701-9664-4931-8754-1a8cae68da06 | 2022-11-01 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE (CPDA-1) SOLUTION | Fenwal, Inc. | f9d7f1b4-7a77-44f9-8924-10b16008b49d | 2022-11-01 | XF417D3PSL | |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) | Fenwal, Inc. | 4a08a9ec-46a5-4fcf-80ee-5c33f1a8b746 | 2022-11-01 | XF417D3PSL | |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Proficient Rx LP | 8d529b4c-85fd-4e50-9443-9080825307bf | 2022-10-01 | Warnings, Adverse reactions | F850569PQR |
| Narcan | NALOXONE HYDROCHLORIDE | Proficient Rx LP | 76b5a1ce-e601-457c-ab35-43533bba4394 | 2022-08-01 | Warnings, Adverse reactions | F850569PQR |
| Addiclenz | BETA VULGARIS, BOLDO, CHELIDONIUM MAJUS, PETROSELINUM SATIVUM, TARAXACUM OFFICINALE, ARSENICUM ALBUM, BISPHENOL A, COBALTUM METALLICUM, CUPRUM METALLICUM, GLYPHOSATE, IODIUM, LYCOPODIUM CLAVATUM, PHOSPHORICUM ACIDUM, SELENIUM METALLICUM, ZINCUM METALLICUM, ASPARTAME, BENZALKONIUM CHLORIDE, FORMALINUM, METHYLENE CHLORIDE, METHYL PARABEN, PROPYL PARABEN, SODIUM BENZOATE, SODIUM CITRATE, TITANIUM DIOXIDE, ZINCUM OXYDATUM | Deseret Biologicals, Inc. | e39235ea-2a2f-44a7-92d6-fb1d428ebabd | 2022-05-12 | Warnings | 1Q73Q2JULR |
| Bio Co-Enzyme Phase | BETA VULGARIS, ASCORBICUM ACIDUM, CYSTEINUM, NATRUM OXALACETICUM, NICOTINAMIDUM, PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, THIAMINUM HYDROCHLORICUM, ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CERIUM OXALICUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, NADIDUM, NATRUM PYRUVICUM, PANTOTHENIC ACID, SUCCINICUM ACIDUM, ADRENALINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, HEPAR SULPHURIS CALCAREUM, SULPHUR, ACONITICUM ACIDUM, CIS-, | Deseret Biologicals, Inc. | e8f6e2ec-ae2e-4bee-b9d3-5f3a2e3daf65 | 2022-05-09 | Warnings | XF417D3PSL |
| ACD Blood-Pack Units (PL 146 PLASTIC) | ANTICOAGULANT CITRATE DEXTROSE (ACD) | Fenwal, Inc. | ba894daa-688e-4a9e-bd74-e71797f951bb | 2022-04-27 | XF417D3PSL | |
| Naloxone Hydrochloride Injection, USP, Auto-Injector | NALOXONE HYDROCHLORIDE | Kaleo, Inc. | b5463553-b775-47a3-8d10-31e01ca1ec72 | 2022-03-11 | Warnings, Adverse reactions | F850569PQR |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | 1Q73Q2JULR XF417D3PSL | |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | International Medication Systems, Limited | d2f5bfa0-933e-46d0-8b1a-9f90e6aaba54 | 2021-12-13 | Warnings, Adverse reactions | F850569PQR |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | XF417D3PSL | |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | Baxter Healthcare Corporation | d04ae2d7-01b9-405d-bb7a-bf2d876ce26a | 2021-07-02 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Mylan Institutional LLC | d96ebf2e-1051-4b5b-b1c6-2543dbbb2d04 | 2021-04-21 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Baxter Healthcare Corporation | 3d8813be-6d22-46f1-ac25-0d8a817a521c | 2020-11-25 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Mylan Institutional LLC | f0932877-1f3b-4d5e-82d2-dd6c53db4730 | 2020-08-17 | Warnings, Adverse reactions | F850569PQR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.